Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response rates and consistent safety data.
Latest Ratings for RVMD
DateFirmActionFromTo Mar 2022StifelUpgradesHoldBuy Nov 2021HC Wainwright & Co.MaintainsBuy Sep 2021StifelInitiates Coverage OnHold